Analyses

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial
MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial…

MAP Pharmaceuticals Presents Analyses Showing LEVADEX Effective when Administered at Various Times in Migraine Cycle …
MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3…